{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:49:26Z","timestamp":1784198966904,"version":"3.55.0"},"reference-count":50,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["8KL2 TR000118"],"award-info":[{"award-number":["8KL2 TR000118"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170345"],"award-info":[{"award-number":["RP170345"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009779","name":"Bladder Cancer Advocacy Network","doi-asserted-by":"publisher","award":["Young Investigator Awards 2016, 2017"],"award-info":[{"award-number":["Young Investigator Awards 2016, 2017"]}],"id":[{"id":"10.13039\/100009779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BC) ranks as the 10th leading cause of cancer\u2010related deaths in the United States. Despite significant advancements in managing BC, including antibody\u2010drug conjugates and immune checkpoint blockers, a significant percentage of patients fail these treatments. This underscores the pressing need to develop methods for identifying novel therapeutic targets, predicting therapy responses, and optimizing personalized treatment strategies for patients. Patient\u2010derived xenograft (PDX) models have the potential to address these challenges. However, these models suffer from limitations, including a consistent rate of tumor acceptance, extended time for tumor growth, and the absence of the donor's immune system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study aimed to address these challenges through a comprehensive comparison of different PDX implantation methods, culminating in the establishment of a PDX cell line for utilization in in\u00a0vivo BC preclinical models. Flow cytometry analysis and total RNA sequencing were used for comparative analysis of original tumor tissue, PDX tumor, and PDX257S cell line.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tumor tissue processing techniques were optimized to enhance the rate of PDX tumor acceptance and shorten the time to tumor development. Furthermore, a PDX cell line, PDX257S, was successfully established and confirmed to exhibit more aggressive and tumorigenic characteristics compared to the original donor tumor tissue. The PDX257S cell line demonstrated faster tumor growth, higher expression of human epithelial cell adhesion molecule, increased mutation burden in BC\u2010associated genes, and significant alterations in BC\u2010related gene expression, compared to the original tumor. The PDX257S cell line was also used to establish a double humanized BC murine model that minimized graft\u2010versus\u2010host disease and is a potential platform for testing novel immune therapeutics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In summary, this study offers an optimized protocol for the consistent establishment of BC PDX tumors. Furthermore, it has also established a novel double\u2010humanized model, demonstrating the potential for drug screening and clinical prognosis in the context of BC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71150","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T10:28:51Z","timestamp":1755080931000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Double\u2010Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for Cancer Immunology Research"],"prefix":"10.1002","volume":"14","author":[{"given":"Niannian","family":"Ji","sequence":"first","affiliation":[{"name":"Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson  San Antonio Texas USA"},{"name":"Department of Urology UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaineb","family":"Hassouneh","sequence":"additional","affiliation":[{"name":"Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson  San Antonio Texas USA"},{"name":"Department of Urology UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Trecarten","sequence":"additional","affiliation":[{"name":"Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson  San Antonio Texas USA"},{"name":"Department of Urology UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen\u2010Ju","family":"Shu","sequence":"additional","affiliation":[{"name":"Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson  San Antonio Texas USA"},{"name":"Department of Urology UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Furman","sequence":"additional","affiliation":[{"name":"Pathology Reference Laboratory  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Curiel","sequence":"additional","affiliation":[{"name":"Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson  San Antonio Texas USA"},{"name":"Division of Hematology\/Medical Oncology at the UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-1338","authenticated-orcid":false,"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[{"name":"Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson  San Antonio Texas USA"},{"name":"Department of Urology UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1974-6075","authenticated-orcid":false,"given":"Neelam","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson  San Antonio Texas USA"},{"name":"Department of Urology UT Health San Antonio  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"National cancer institute surveillance epidemiology and end results program \u201cSEER is an authoritative source for cancer statistics in the United States.\u201dhttps:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.028"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.01.015"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.12.020"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6610-7"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0328"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.696716"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0001"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019101654"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.19"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx416"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3954"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20211986"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044664"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0285"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03236-y"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1614857"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00352-4"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.4161\/cam.18953"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22465-w"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.687786"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46652-4"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33794"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.06.165"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0189"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq929"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2010.04.003"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.03.004"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.02.008"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.07.006"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092062"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1260"},{"issue":"4","key":"e_1_2_11_37_1","first-page":"281","article-title":"Growth of Human Tumor Xenografts Implanted Under the Renal Capsule of Normal Immunocompetent Mice","volume":"47","author":"Bogden A. E.","year":"1979","journal-title":"Experimental Cell Biology"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3974"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100745"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039294"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12123"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.06.053"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01220.x"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134346"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201700740R"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep35854"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15885-7"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.08.036"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1237-1"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3510"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143695"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71150","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:12:39Z","timestamp":1772989959000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/cam4.71150"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71150","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2024-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71150"}}